These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7410539)

  • 1. Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology.
    Camanni F; Genazzani AR; Massara F; de Leo V; Molinatti GM; Müller EE
    J Clin Endocrinol Metab; 1980 Sep; 51(3):650-3. PubMed ID: 7410539
    [No Abstract]   [Full Text] [Related]  

  • 2. Nomifensine in the diagnosis of hyperprolactinemia.
    Gullo D; Carmina E; Mogavero G; Perino A; Venezia R
    Acta Eur Fertil; 1981 Dec; 12(4):299-306. PubMed ID: 7342611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of nomifensine administration to discriminate between tumorous and nontumorous hyperprolactinemia.
    Ferrari C; Crosignani PG; Caldara R; Picciotti MC; Malinverni A; Barattini B; Rampini P; Telloli P
    J Clin Endocrinol Metab; 1980 Jan; 50(1):23-6. PubMed ID: 7188615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approach to the diagnosis of hyperprolactinemic states: the nomifensine and domperidone tests.
    Molinatti GM; Camanni F; Cocchi D; De Leo V; Genazzni AR; Massara F; Muller EE
    Panminerva Med; 1981; 23(1):5-10. PubMed ID: 7290727
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors.
    Kamoi K; Tchuchida I; Sato H; Tanaka R; Ishiguro T; Kaneko K; Iwasaki Y; Shibata A
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1285-7. PubMed ID: 7298805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomifensine: diagnostic test in hyperprolactinemic states.
    Müller EE; Genazzani AR; Murru S
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1352-7. PubMed ID: 263356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone.
    Massara F; Genazzani AR; Camanni F; De Leo V; Molinatti GM; Müller EE
    Fertil Steril; 1981 Feb; 35(2):149-54. PubMed ID: 7202740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some critical considerations on the use of the nomifensine test in the hyperprolactinaemic syndrome.
    D'Agata R; Aliffi A; Vicari E; Volpicelli D; Mongioì A; Gulizia S
    Horm Res; 1981; 14(3):148-54. PubMed ID: 7286887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas.
    Iannotta F; Fachinetti P; Fachinetti A; Pinotti G; Usellini L
    J Endocrinol Invest; 1983 Oct; 6(5):353-8. PubMed ID: 6420458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentric experience on the acute effect of nomifensine in hyperprolactinemic women.
    Minuto F; Barbarino A; Baviera G; Mazzocchi G; De Marinis L; Leonardi R; Bernasconi D; Menini E; Maira G; Anile C
    J Endocrinol Invest; 1984 Apr; 7(2):137-40. PubMed ID: 6725869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agreement of prolactin response to cimetidine and nomifensine in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia.
    Iodice M; Lombardi G; Tommaselli A; Rossi R; Annunziato L; Minozzi M
    Neuroendocrinology; 1982 Nov; 35(5):333-5. PubMed ID: 7145025
    [No Abstract]   [Full Text] [Related]  

  • 12. A new pharmacological approach to the diagnosis of hyperprolactinaemic states: the nomifensine test.
    Genazzani AR; Camanni F; Massara F; Picciolini E; Cocchi D; Belforte L; Müller EE
    Acta Endocrinol (Copenh); 1980 Feb; 93(2):139-48. PubMed ID: 6769270
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of central nervous system dopaminergic activation on prolactin secretion in man: evidence for a common central defect in hyperprolactinemic patients with and without radiological signs of pituitary tumors.
    Crosignani PG; Ferrari C; Malinverni A; Barbieri C; Mattei AM; Caldara R; Rocchetti M
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1068-73. PubMed ID: 7419682
    [No Abstract]   [Full Text] [Related]  

  • 14. [Indirect dopamine agonists and direct dopamine antagonists in the diagnosis of hyperprolactinemia].
    De Leo V; Massafra C; La Marca S; De Leo M; Venturi C; Urbani TM; Genazzani AR
    Boll Soc Ital Biol Sper; 1982 Aug; 58(16):1025-31. PubMed ID: 7138672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of nomifensine on prolactin secretion in patients with suspected pituitary microadenoma.
    Jeske W; Stopińska U
    Endokrynol Pol; 1981; 32(1):17-24. PubMed ID: 7250073
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia.
    Dallabonzana D; Spelta B; Botalla L; Oppizzi G; Silvestrini F; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1125-8. PubMed ID: 7076795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in the hormonal detection of pituitary prolactin adenoma].
    De Gennes JL; Turpin G; Heshmati HM; Carayon A
    Ann Med Interne (Paris); 1982; 133(1):12-6. PubMed ID: 7065584
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of bromocriptine as a diagnostic and therapeutic tool in hyperprolactinemic states.
    Abraham G
    Prog Clin Biol Res; 1982; 112 Pt A():255-73. PubMed ID: 7163300
    [No Abstract]   [Full Text] [Related]  

  • 19. Nomifensine-induced pregnancy in a hyperprolactinemic woman.
    Genazzani AR; De Leo V; Camanni F; Müller EE
    J Endocrinol Invest; 1982; 5(2):129-30. PubMed ID: 7096920
    [No Abstract]   [Full Text] [Related]  

  • 20. [Differential diagnosis of hyperprolactinemia].
    Takeda R; Minagawa F; Nakabayashi H
    Nihon Rinsho; 1986 Mar; 44(3):671-7. PubMed ID: 2874247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.